Literature DB >> 25058872

Structural characterization of the C3 domain of cardiac myosin binding protein C and its hypertrophic cardiomyopathy-related R502W mutant.

Xiaolu Linda Zhang1, Soumya De, Lawrence P McIntosh, Mark Paetzel.   

Abstract

Human cardiac myosin binding protein C (cMyBP-C), a thick filament protein found within the sarcomere of cardiac muscle, regulates muscle contraction and is essential for proper muscle function. Hypertrophic cardiomyopathy (HCM), a genetic disease affecting 1 in 500 people, is the major cause of death in young athletes. It is caused by genetic mutations within sarcomeric proteins. Forty-two percent of the HCM-related mutations are found in cMyBP-C. Here we present the nuclear magnetic resonance-derived structural ensembles of the wild-type cMyBP-C C3 domain and its HCM-related R502W mutant. The C3 domain adopts an immunoglobulin-like fold, and mutation of the exposed Arg502 to a tryptophan does not perturb its structure, dynamics, or stability. However, the R502W mutation does alter the predicted electrostatic properties of the C3 domain. We hypothesize that this mutation, and other HCM-linked mutations found within the same domain, may directly disrupt the interaction of cMyBP-C with other sarcomeric proteins.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25058872     DOI: 10.1021/bi500784g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes.

Authors:  Ella Field; Gabrielle Norrish; Vanessa Acquaah; Kathleen Dady; Marcos Nicolas Cicerchia; Juan Pablo Ochoa; Petros Syrris; Karen McLeod; Ruth McGowan; Hannah Fell; Luis R Lopes; Elena Cervi; Juan Pablo Pablo Kaski
Journal:  J Med Genet       Date:  2021-08-16       Impact factor: 5.941

2.  CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation.

Authors:  Mika Tarkiainen; Petri Sipola; Mikko Jalanko; Tiina Heliö; Pertti Jääskeläinen; Kati Kivelä; Mika Laine; Kirsi Lauerma; Johanna Kuusisto
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

3.  Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy.

Authors:  Carmen Suay-Corredera; Maria Rosaria Pricolo; Diana Velázquez-Carreras; Divya Pathak; Neha Nandwani; Carolina Pimenta-Lopes; David Sánchez-Ortiz; Iñigo Urrutia-Irazabal; Silvia Vilches; Fernando Dominguez; Giulia Frisso; Lorenzo Monserrat; Pablo García-Pavía; David de Sancho; James A Spudich; Kathleen M Ruppel; Elías Herrero-Galán; Jorge Alegre-Cebollada
Journal:  ACS Nano       Date:  2021-06-01       Impact factor: 18.027

4.  Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy.

Authors:  Mika Tarkiainen; Petri Sipola; Mikko Jalanko; Tiina Heliö; Mika Laine; Vesa Järvinen; Kaisu Häyrinen; Kirsi Lauerma; Johanna Kuusisto
Journal:  J Cardiovasc Magn Reson       Date:  2016-06-04       Impact factor: 5.364

5.  Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy.

Authors:  Adam S Helms; Andrea D Thompson; Amelia A Glazier; Neha Hafeez; Samat Kabani; Juliani Rodriguez; Jaime M Yob; Helen Woolcock; Francesco Mazzarotto; Neal K Lakdawala; Samuel G Wittekind; Alexandre C Pereira; Daniel L Jacoby; Steven D Colan; Euan A Ashley; Sara Saberi; James S Ware; Jodie Ingles; Christopher Semsarian; Michelle Michels; Iacopo Olivotto; Carolyn Y Ho; Sharlene M Day
Journal:  Circ Genom Precis Med       Date:  2020-08-25

6.  Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.

Authors:  Irene Méndez; Ana Isabel Fernández; Maria Ángeles Espinosa; Sofía Cuenca; Rebeca Lorca; José Fernando Rodríguez; Maria Tamargo; Marta García-Montero; Cristina Gómez; Silvia Vilches; Nélida Vázquez; Reyes Álvarez; Constancio Medrano; Raquel Yotti; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Open Heart       Date:  2021-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.